Goldman, Sachs

Goldman Sachs Adjusts Kontron Stake Amid Company's Share Buyback Initiative

03.04.2026 - 05:37:01 | boerse-global.de

Kontron launches a €50M buyback after a weak share price start. Goldman Sachs slightly reduces its voting rights stake, held mostly via financial instruments.

Goldman Sachs Adjusts Kontron Stake Amid Company's Share Buyback Initiative - Foto: über boerse-global.de

The technology firm Kontron has initiated market support measures following a challenging start to the year. These corporate actions coincide with a notable portfolio adjustment by a major institutional shareholder, unfolding against a backdrop of tempered profit forecasts and costly restructuring efforts.

A Major Shareholder Recalibrates

In a recent regulatory filing, the US investment bank Goldman Sachs reported a change in its voting rights position in Kontron. The bank's total stake now stands at 4.31% of voting rights, a slight decrease from its previous holding of 4.43%. The composition of this interest is noteworthy: direct shareholdings account for only 0.40% of the total, with the substantial majority of the position being held through financial instruments such as securities lending and swaps.

Management Deploys Capital to Support Shares

Responding directly to share price weakness in recent weeks, Kontron's management activated its previously announced share repurchase program at the end of March. In the program's initial two trading days, the company acquired approximately 188,000 of its own shares across various European trading venues. The total consideration for these purchases amounted to roughly €3.5 million, achieved at an average price just above €18.60 per share. The board has authorized a total budget of up to €50 million to buy back a maximum of 2.9 million shares by the end of September 2026.

Should investors sell immediately? Or is it worth buying Kontron?

Earnings Outlook and Restructuring Weigh on Sentiment

Kontron's desire to bolster its market valuation is understandable given its year-to-date performance. Since the beginning of January, the share price has declined by 17.75%, closing at €19.28 in the latest session. This downward pressure was recently exacerbated by a disappointing financial forecast. The company's targeted EBITDA of €225 million for 2026 fell significantly short of the average analyst estimate of €246 million. Furthermore, the planned restructuring of its loss-making clean-tech business, which entails one-time costs of approximately €25 million, is placing additional strain on the current financial statements.

Despite near-term headwinds, the leadership team expresses confidence in its long-term strategic direction. Management is targeting nearly a doubling of EBITDA to €420 million by 2030. This optimism is supported by a growing order backlog, which has now reached €2.5 billion. Analysts at Jefferies have maintained their "buy" recommendation on the stock with a price target of €27, indicating that experts anticipate an operational recovery for the company in the medium term, even amidst its current transitional phase.

Ad

Kontron Stock: New Analysis - 3 April

Fresh Kontron information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Kontron analysis...

So schätzen die Börsenprofis Goldman Aktien ein!

<b>So schätzen die Börsenprofis  Goldman Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
AT0000A0E9W5 | GOLDMAN | boerse | 69061425 |

Weitere Meldungen

ANALYSE-FLASH: Goldman senkt Ziel für Henkel auf 70 Euro - 'Sell' Die US-Investmentbank Goldman Sachs hat das Kursziel für Henkel DE0006048432 vor Quartalszahlen von 73 auf 70 Euro gesenkt und die Einstufung auf "Sell" belassen. (Boerse, 02.04.2026 - 12:35) weiterlesen...

ANALYSE-FLASH: Goldman hebt Ziel für Evonik auf 20 Euro - 'Buy' Die US-Investmentbank Goldman Sachs hat das Kursziel für Evonik DE000EVNK013 vor Quartalszahlen von 18 auf 20 Euro angehoben und die Einstufung auf "Buy" belassen. (Boerse, 02.04.2026 - 11:20) weiterlesen...

ANALYSE-FLASH: Goldman hebt Rheinmetall auf 'European Conviction List' - 'Buy' Die US-Investmentbank Goldman Sachs hat die Rheinmetall-Aktie DE0007030009 in die "European Conviction List" für besonders aussichtsreiche Werte aufgenommen. (Boerse, 01.04.2026 - 19:05) weiterlesen...

AKTIE IM FOKUS: Goldman Sachs treibt kräftige Rheinmetall-Erholung voran Die Aktie von Rheinmetall DE0007030009 hat sich am Mittwoch im freundlichen Gesamtmarkt weiter von ihrem am Montag erreichten Elf-Monats-Tief nach oben hin abgesetzt. (Boerse, 01.04.2026 - 16:51) weiterlesen...

ANALYSE-FLASH: Goldman senkt Ziel für Lanxess auf 21 Euro - 'Neutral' Die US-Investmentbank Goldman Sachs hat das Kursziel für Lanxess DE0005470405 vor Zahlen zum ersten Quartal von 23 auf 21 Euro gesenkt und die Einstufung auf "Neutral" belassen. (Boerse, 01.04.2026 - 12:34) weiterlesen...

ANALYSE-FLASH: Goldman hebt Sartorius Stedim Biotech auf 'Buy' - Ziel gesenkt Die US-Investmentbank Goldman Sachs hat das Kursziel für Sartorius Stedim FR0013154002 von 235 auf 214 Euro gesenkt, die Aktien aber von "Neutral" auf "Buy" hochgestuft. (Boerse, 30.03.2026 - 09:04) weiterlesen...